Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite intergroup clinical trials conducted in Europe and North America, outcomes for high risk patients with this disease have not significantly improved in the last several decades, and survival of metastatic or relapsed disease remains extremely poor. Accrual into new clinical trials is slow and difficult, so in vitro cell-line research and in vivo xenograft models present an attractive alternative for preclinical research for this cancer type. Currently, 30 commonly used human RMS cell lines exist, with differing origins, karyotypes, histologies, and methods of validation. Selecting an appropriate cell line for RMS research has important implications for outcomes. There are also potential pitfalls in using certain cell lines including contamination with murine stromal cells, cross-contamination between cell lines, discordance between the cell line and its associated original tumor, imposter cell lines, and nomenclature errors that result in the circulation of two or more presumed unique cell lines that are actually from the same origin. These pitfalls can be avoided by testing for species-specific isoenzymes, microarray analysis, assays for subtype-specific fusion products, and short tandem repeat analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma
Galili, N., Davis, R. J., Fredericks, W. J., Mukhopadhyay, S., Rauscher, F. J., Emanuel, B. S., Rovera, G., & Barr, F. G. (1993) · Nature Genetics · doi:10.1038/ng1193-230 · Cited by 892 · cited 2×
“For example, the “RH18” cell line can refer to the version not bearing the fusion gene (59), or the version bearing the fusion gene (60), which may have emerged from the original cell culture.”
BackgroundResultSelf-citationRearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma
Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Rovera, G., & Emanuel, B. S. (1993) · Nature Genetics · doi:10.1038/ng0293-113 · Cited by 555 · cited 1×
“Though FOXO1 does localize to the 13q14 region, Northern blot studies of this line with a FOXO1 probe failed to show any evidence of a novel-sized transcript, thus suggesting that FOXO1 is not affected by these translocations (52).”
BackgroundSelf-citationTrends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005
Ognjanovic, S., Linabery, A. M., Charbonneau, B., & Ross, J. A. (2009) · Cancer · doi:10.1002/cncr.24465 · Cited by 497 · cited 10×
“RH41 (RH4) Lung metastasis 7-year-old female Yes t(2;13), TP53 mutation Yes”
BackgroundInfluentialThe pediatric preclinical testing program: Description of models and early testing results
Houghton, P. J., Morton, C. L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E. A., Zhang, W., Lock, R., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21078 · Cited by 480
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Khan, J. I., Simon, R., Bittner, M. L., Chen, Y., Leighton, S. B., Pohida, T. J., Smith, P. D., Jiang, Y. Y., Gooden, G. C., Trent, J. M., et al. (1998) · PubMed · Cited by 480
Short tandem repeat profiling provides an international reference standard for human cell lines
Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A., Dirks, W. G., Packer, P., Toji, L. H., Ohno, T., Tanabe, H., Arlett, C. F., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121616198 · Cited by 478 · cited 2×
“and low cost of this method are the strengths supporting its use as a standard of cell line authentication (87).”
MethodCoamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
Khatib, Z. A., Matsushime, H., Valentine, M. B., Shapiro, D. N., Sherr, C. J., & Look, A. T. (1993) · PubMed · Cited by 389
Cultivation in vitro of cells derived from a human rhabdomyosarcoma
McAllister, R. M., Melnyk, J., Finklestein, J. Z., Adams, E. C., & Gardner, M. B. (1969) · Cancer · doi:10.1002/1097-0142(196909)24:3<520::aid-cncr2820240313>3.0.co;2-m · Cited by 323 · cited 1×
“RD RD was derived directly from biopsy specimens of a 7-year-old female with a pelvic RMS previously treated with cyclophosphamide and radiation and found to have refractory disease (27).”
MethodA specific chromosomal abnormality in rhabdomyosarcoma
Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D., Webber, B. L., Houghton, P. J., & Green, A. A. (1987) · Cytogenetic and Genome Research · doi:10.1159/000132446 · Cited by 322 · cited 5×
“An alveolar RMS cell-line labeled RMS13 (39, 69) is thought by some investigators to be related to RH30, perhaps derived from the same patient tumor as RH30, but this is not clear.”
BackgroundInfluentialPPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215634 · Cited by 276 · cited 6×
“It can now be obtained from Dr. Frederic Barr at the National Cancer Institute, Bethesda, MD, USA (personal communication, Dr. www.frontiersin.org July 2013 | Volume 3 | Article 183 | 5 Frederic Barr).”
Influential
Cited by
Yu, P. Y., Gardner, H. L., Roberts, R., Cam, H., Hariharan, S., Ren, L., LeBlanc, A. K., Xiao, H., Lin, J., Guttridge, D. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181885 · Cited by 17
Metadata
- Authors
- Hinson, A. R. P., Jones, R., Crose, L. E. S., Belyea, B. C., Barr, F. G., & Linardic, C. M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 183-183
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2076819367
- Cited by
- 192
- References
- 64
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.